Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.

Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
29 Feb 2024
Historique:
revised: 16 01 2024
received: 25 08 2023
accepted: 18 02 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: aheadofprint

Résumé

Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.

Identifiants

DOI: 10.1002/ajh.27280 PMID: 38425185
pubmed: 38425185
doi: 10.1002/ajh.27280
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Austrian Forum Against Cancer
Organisme : Amgen Research Grant

Informations de copyright

© 2024 Wiley Periodicals LLC.

Références

Malacrida A, Semperboni S, Di Domizio A, et al. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect. Sci Rep. 2021;11(1):10523.
Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(2):139-150.
Mina R, Musto P, Rota-Scalabrini D, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24(1):64-76.
Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784-792.
Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901-2912.
Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917.

Auteurs

Heinz Ludwig (H)

Department of Medicine I, Clinic Ottakring, Wilhelminen Cancer Research Institute, Vienna, Austria.
ORCID: 0000-0002-3302-8726

Thomas Melchardt (T)

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.

Siegfried Sormann (S)

Department of Hematology, University Clinic for Internal Medicine, Graz, Austria.

Martin Schreder (M)

Department of Medicine I, Clinic Ottakring, Vienna, Austria.

Johannes Andel (J)

Department of Internal Medicine II, Pyhrn-Eisenwurzen Klinikum Steyr, Steyr, Austria.

Bernd Hartmann (B)

Department of Internal Medicine II, LKH Rankweil, Rankweil, Austria.

Christoph Tinchon (C)

Department for Hematology, Oncology and Palliative Care, LKH Hochsteiermark, Standort Leoben, Standort Leoben, Austria.

Niklas Zojer (N)

Department of Medicine I, Clinic Ottakring, Vienna, Austria.

Eberhard Gunsilius (E)

Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.

Klaus Podar (K)

Department of Internal Medicine II, University Hospital Krems, Krems an der Donau, Austria.
Molecular Oncology and Hematology Unit, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.

Alexander Egle (A)

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.
ORCID: 0000-0003-0648-4416

Wolfgang Willenbacher (W)

Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.
syndena GmbH, Connect to Cure, Innsbruck, Austria.

Ewald Wöll (E)

Department of Internal Medicine, St. Vinzenz Krankenhaus Zams, Zams, Austria.

Reinhard Ruckser (R)

Department of Medicine II, Clinic Donaustadt, Vienna, Austria.

Boris Bozic (B)

Department of Medicine II, Clinic Donaustadt, Vienna, Austria.

Maria-Theresa Krauth (MT)

University Clinic for Internal Medicine I, AKH, Medical University of Vienna, Vienna, Austria.

Andreas Petzer (A)

Department of Internal Medicine I, BHS Linz, Linz, Austria.

Clemens Schmitt (C)

Clinic for Internal Medicine 3, Kepler University Clinic Linz, Linz, Austria.

Sigrid Machherndl-Spandl (S)

Department of Internal Medicine I, Elisabethinen, Linz, Austria.

Hermine Agis (H)

Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria.
ORCID: 0000-0002-1125-0211

Michael Fillitz (M)

Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria.

Song-Yau Wang (SY)

Medical Clinic and Policlinic I, University Clinic Leipzig, Leipzig, Germany.

August Zabernigg (A)

Department of Internal Medicine, Kufstein County Hospital, Kufstein, Austria.

Stefan Knop (S)

Klinik für Innere Medizin 5, Schwerpunkt Onkologie/Hämatologie, Klinikum Nürnberg Nord, Nürnberg, Germany.

Bruno Paiva (B)

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), CCUN, IDISNA, Pamplona, Spain.

Richard Greil (R)

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria.

Classifications MeSH